RUBY - Rubius Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.68
+0.22 (+2.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.46
Open8.46
Bid8.22 x 800
Ask8.99 x 800
Day's Range8.26 - 8.79
52 Week Range6.96 - 20.04
Volume167,558
Avg. Volume390,939
Market Cap692.672M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.87
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.83
  • GlobeNewswire

    Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU). The trial is designed to evaluate the safety and pharmacokinetics of RTX-134 in adult patients with PKU. “Phenylketonuria is a devastating metabolic disorder that can lead to serious cognitive impairment if not properly treated,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius.

  • BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
    Zacks

    BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

    BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

  • 'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment
    American City Business Journals

    'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment

    The CEO of a Cambridge biotech startup promised the company would “deliver in 2020” after announcing a second delay with its first-ever clinical trial.

  • GlobeNewswire

    Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced 2020 objectives and operational updates. Pablo J. Cagnoni, M.D., chief executive officer, will present these updates and review 2019 accomplishments today at 9:00 a.m. PST / 12:00 p.m. EST at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

  • GlobeNewswire

    Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020. Dr. Turka, a distinguished physician-scientist in autoimmunity and translational immunology, joins Rubius from Rheos Medicines, where he was a co-founder and served as chief scientific officer. “Larry brings to Rubius exceptional insights and an extraordinary record of scientific achievement in immune-mediated diseases,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics.

  • GlobeNewswire

    Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

  • GlobeNewswire

    Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Christina Coughlin, M.D., Ph.D., as the Company’s chief medical officer, effective January 6, 2020. With Dr. Coughlin’s appointment, Chris Carpenter, M.D., Ph.D., Rubius’ previous chief medical officer, is transitioning to a scientific advisory role.

  • Rubius Therapeutics, Inc. (RUBY): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Rubius Therapeutics, Inc. (RUBY): Are Hedge Funds Right About This Stock?

    We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Rubius Therapeutics, Inc. (NASDAQ:RUBY) based on that […]

  • Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
    PR Newswire

    Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

  • GlobeNewswire

    Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors. Dr. Prener most recently served as the chief executive officer of Freeline Therapeutics, Ltd. Also today, Rubius announced that Robert (Bob) S. Langer, Sc.D., is stepping down from his role on the board of directors, effective today, but will continue to serve the Company through a scientific advisory role.

  • GlobeNewswire

    Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    CAMBRIDGE, Mass., Nov. 14, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

  • GlobeNewswire

    Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 12, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

  • GlobeNewswire

    Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary

    CAMBRIDGE, Mass., Nov. 12, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

  • GlobeNewswire

    Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    CAMBRIDGE, Mass., Nov. 08, 2019 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

  • GlobeNewswire

    Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 05, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

  • Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer
    PR Newswire

    Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer

    BOSTON, Nov. 4, 2019 /PRNewswire/ -- Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of Nathan J. Dowden as Chief Operating Officer. Mr. Dowden was most recently Senior Vice President of Strategy and Corporate Development at Rubius Therapeutics (RUBY) and joins Entrada with almost 30 years of strategy, investment and operational experience in the healthcare field. "Nate brings an extensive track record of both strategic and operational expertise from his time spent as a life sciences strategy consultant and the role he has played in the start-up and growth of several successful biotechnology companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.

  • Should You Buy Rubius Therapeutics, Inc. (RUBY)?
    Insider Monkey

    Should You Buy Rubius Therapeutics, Inc. (RUBY)?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • GlobeNewswire

    Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences

    CAMBRIDGE, Mass., Oct. 17, 2019 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

  • GlobeNewswire

    Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

  • GlobeNewswire

    Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress

    On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 -- Rubius Therapeutics, Inc..

  • GlobeNewswire

    Rubius Therapeutics to Announce Second Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Aug. 07, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.

  • GlobeNewswire

    Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Kris Elverum as senior vice president of business development and strategy. In his role, Kris will be responsible for developing the Company’s corporate strategy and creating and executing new business development opportunities. “As we continue to advance our promising pipeline of Red Cell Therapeutics™ for the potential treatment of rare diseases, cancer and autoimmune diseases, our corporate growth strategy is a crucial part of bringing our new treatment options to patients worldwide,” said Pablo J. Cagnoni, M.D., chief executive officer.

  • Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44%
    Simply Wall St.

    Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44%

    The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...

  • GlobeNewswire

    Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs

    Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of allogeneic, off-the-shelf cellular medicines, today announced the issuance of three patents from the U.S. Patent and Trademark Office (USPTO) related to its rare disease and oncology programs and platforms. The third patent, the Company’s first issued composition of matter patent in immuno-oncology, relates to human cells having a checkpoint inhibitor linked to the cell surface. In total, Rubius Therapeutics has 29 patent families and more than 125 pending patent applications worldwide.

  • GlobeNewswire

    Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference

    CAMBRIDGE, Mass., May 28, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.